key: cord-0695984-2sf4u7ad
authors: Fragkou, Paraskevi C.; De Angelis, Giulia; Menchinelli, Giulia; Can, Fusun; Garcia, Federico; Morfin-Sherpa, Florence; Dimopoulou, Dimitra; Mack, Elisabeth; de Salazar, Adolfo; Grossi, Adriano; Lytras, Theodore; Skevaki, Chrysanthi
title: ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
date: 2022-02-23
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.011
sha: 45d2971545b6f8f0c5fdba9a607fca89088e9076
doc_id: 695984
cord_uid: 2sf4u7ad

SCOPE: The objective of these guidelines is to identify the most appropriate diagnostic test and/or diagnostic approach for SARS-CoV-2. The recommendations are intended to provide guidance to clinicians, clinical microbiologists, other health care personnel, and decision makers. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search focusing on systematic reviews with a third panelist involved in case of inconsistent results. Quality of evidence assessment was based on the GRADE-ADOLOPMENT approach. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: A total of 43 PICO questions were selected that involve the following types of populations: 1) patients with signs and symptoms of COVID-19; 2) travelers, healthcare workers, and other individuals at risk for exposure to SARS-CoV-2; 3) asymptomatic individuals and 4) close contacts of patients infected with SARS-CoV-2. The type of diagnostic test (commercial rapid nucleic acid amplification tests, and rapid antigen detection), biomaterial, time since onset of symptoms/contact with an infectious case, age, disease severity, and risk of developing severe disease are also taken into consideration.

QUADAS-2 for any new study retrieved during the evidence syntheses update, if performed 1 (see Supplementary Methods). The risk of bias was judged very serious or serious if all or 2 more/equal than a half of studies, respectively, have high or unclear concern regarding all or 3 one to three QUADAS-2 domains. The risk of bias was judged not serious in any other case. 4 Indirectness 5 Indirectness was judged for all studies based on QUADAS-2 tool concerns for 6 applicability for patient selection, index test, and reference standard. The QUADAS-2 7 applicability assessment of studies included in the original systematic review was adopted; two 8 panel members independently assessed the QUADAS-2 applicability for any new study 9 retrieved during the systematic review update, if performed. The indirectness was judged very 10 serious or serious if all or more/equal than half of studies, respectively, have high or unclear 11 concern regarding all or one to two QUADAS-2 domains for applicability concern. The 12 indirectness was judged not serious in any other case. Furthermore, evidence was judged 13 indirect if marked differences in population respect to the review question were suspected.

14 Inconsistency 15 Heterogeneity of results was assessed statistically by the I 2 test. We searched for a 16 plausible source of heterogeneity by subgroup analyses according to the most plausible reason 17 of heterogeneity, i.e. the type of samples, the type of test and the quality of the studies. These 18 sub-analyses were performed only if subgroups included at least 4 or more studies. If a plausible 19 explanation for heterogeneity was not identified, the quality of evidence was downgraded.. 20 Inconsistency was judged very serious if high and unexplained heterogeneity (I 2 >90%) was 21 detected. Inconsistency was judged not serious if either low (I 2 <50%) or otherwise explained 22 through subgroup analyses. The inconsistency was judged serious in any other case. 23 Imprecision 24 J o u r n a l P r e -p r o o f children may not always be able to produce saliva on demand, and in such cases nasopharyngeal 1 samples are still preferred. Notwithstanding, the available data suggest that the accuracy of 2 saliva NAAT is not as high as nasopharyngeal NAAT. 3 4 B: Travelers from areas with low and high COVID-19 prevalence, healthcare workers, 5 and asymptomatic individuals at risk for exposure 6 The quality of the available evidence for all PICOs prioritized for individuals at high 7 risk of exposure to COVID-19 was very low. Therefore, the strength of recommendation for all 8 PICOs in this section is weak. NAAT driven by questioning for contact history or high-risk 9 exposure is very inaccurate, with very low sensitivity. Despite the very low quality of evidence, 10 the panel recommended against the use of NAAT driven by questioning for contact history or 11 exposure in returning travelers from areas of low and high prevalence of COVID-19, healthcare 12 workers, and asymptomatic individuals at risk for exposure instead of universal NAAT testing. As for all previous PICOs, quality of available evidence for asymptomatic individuals and close 16 contacts was very low; thus all recommendations are weak. 17 Rapid antigen testing 18 In asymptomatic individuals and those with close contact with an infected person, the 19 use of laboratory-based NAAT should be preferred over rapid antigen testing for diagnosis of 20 COVID-19. The panel based its recommendations regarding rapid antigen testing on evidence 21 from studies examining mainly the accuracy of first-and second-generation antigen tests that 22 are not as accurate as the third-generation ones [11] . 23 J o u r n a l P r e -p r o o f NAAT in saliva samples 1 In asymptomatic children <12 years old (with or without close contact), NAAT in saliva 2 samples was recommended over NAAT on nasopharyngeal swab samples for diagnosis of 3 COVID-19 considering the accuracy of the test, the large anticipated benefits and small harm, 4 low amount of resources, small incremental cost relative to net benefits, acceptability, and 5 feasibility of the test. In patients ≥12 years old, NAAT on nasopharyngeal samples should be 6 preferred, also considering that young children may not produce saliva on command. questions should also be highlighted, and very little data is available regarding the clinical 20 impact (treatment, isolation, hospitalization) of these tests. 21 It is further noted that several methodological challenges were encountered that could be Among the limitations of the present guidelines is the very low quality of evidence and 3 lack of dedicated resources to update specific evidence syntheses. Furthermore, poorly 4 disclosed methodological details in relevant meta-analyses did not allow reproducibility of 5 literature searches. We also included reagents for SARS-CoV-2 testing independently of the 6 biomaterial for which they were optimized. We may thus not exclude the possibility that any 7 unfavorable performance of a group of tests (e.g. pooled sensitivity of antigen tests) is due to 8 diluting the favorable performance of tests, which are indeed optimized for one or another 9 biomaterial. We also did not distinguish between different saliva samples, which may perform 10 differently, and thus cannot draw more specific conclusions in this regard. In addition, it should 11 be mentioned that this is not a systematic review, but rather guideline recommendations based 12 on GRADE ADOLOPMENT methodology, which by definition is based on updating (if 13 applicable) existing moderate to high quality already (or preprint) published evidence 14 syntheses. Lastly, consensus was reached by a simple majority vote and not through consensus Updating: the panel will meet once a month to assess the need for further updates. Healthcare Workers Exposed to COVID19 using Rapid Antigen Detection. medRxiv. In asymptomatic populations at risk for exposure, should surveys for contact history with known or suspected exposures within less than 7 days to infected people followed by NAAT be used compared to universal NAAT to diagnose COVID-19?

In asymptomatic populations at risk for exposure, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures within less than 7 days in addition to NAAT for diagnosis of COVID-19.

[119-122] 5 In asymptomatic populations at risk for exposure, should surveys for contact history with known or suspected exposures above 7 days to infected people followed by NAAT be used compared to universal NAAT to diagnose COVID-19?

In asymptomatic populations at risk for exposure, we suggest the use of universal NAAT versus survey for contact history with known or suspected exposures above 7 days in *Strength of recommendation (strong against, weak against, in research only, weak for, strong for). 1 **Overall certainty of the evidence (high, moderate, low, very low). Table 3 . PICO questions and recommendations in asymptomatic individuals and those with close contact with an infected person. J o u r n a l P r e -p r o o f 10 5

In asymptomatic people should rapid antigen test be used as compared to laboratory based NAAT in nonnasopharyngeal/non-saliva samples to diagnose COVID-19?

In asymptomatic people, we suggest the use of laboratory-based NAAT in nonnasopharyngeal/non-saliva samples versus rapid antigen testing in non-nasopharyngeal/non-saliva for diagnosis of COVID-19. 

Characteristics of and Important Lessons From the Coronavirus